A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy
NCT ID: NCT05068921
Last Updated: 2021-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
40 participants
INTERVENTIONAL
2021-12-09
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TQB2858
TQB2858 injection: once every 3 weeks, 1800mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.
TQB2858 injection
TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TQB2858 injection
TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
a) Cervical cancer confirmed by histopathology, including squamous carcinoma, adenocarcinoma and adenosquamous carcinoma; b) Have received ≥1 line of platinum-containing chemotherapy (at least ≥3 cycles of platinum-containing chemotherapy) in the past, and have disease progression or recurrence during or after treatment; c) Confirmed presence of at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors(RECIST) 1.1 standard;
* 2\) Aged: 18 \~ 75 years old
* 3)Physical condition score( Eastern Cooperative Oncology Group(ECOG) score): 0\~1
* 4\) estimated survival time ≥ 3 months
* 5)The main organs function well and meet the following standards:
a) Routine blood examination standards (without blood transfusion or correction with hematopoietic stimulating factor drugs within 14 days before screening):Hemoglobin (HGB) ≥80 g/L; Neutrophil count (NEUT) ≥ 1.5×109/L; Platelets (PLT)≥90×109 /L; b) Biochemical examination: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (Primary hepatobiliary tumor or liver metastasis: ALT, AST≤ 5×ULN ); Total bilirubin (TBIL) ≤1.5×ULN (Gilbert syndrome patients: TBIL≤ 3×ULN); Creatinine (CRE) ≤ 1.5×ULN or creatinine clearance ≥ 60 mL /min; c) Blood coagulation function: activated partial thrombin time (APTT), international standardized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN (without anticoagulant therapy); d) Left ventricular ejection fraction (LVEF) ≥ 50%;
* 6\) Female subjects of childbearing age should agree to use effective contraceptive measures (such as intrauterine device , birth control pills or condoms) during the study period and within 6 months after the end of the study, and have a negative serum pregnancy test within 7 days before the study enrollment and must be non-lactating subjects;
* 7）The subjects voluntarily joined the study, signed the informed consent form, and had good compliance.
Exclusion Criteria
1. the presence of other malignant tumors within 2 years or current co-occurrence . The following two conditions can be included: other malignant tumors treated by single surgery, achieved R0 resection and no recurrence and metastasis; Cured cervical carcinoma in situ (only applicable to the first stage), non-melanoma skin cancer, nasopharyngeal carcinoma, and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basal membrane)\];
2. Pathological findings of mucinous adenocarcinoma, clear cell adenocarcinoma, neuroendocrine tumor and other special pathological types (only applicable to the second stage);
3. Evaluation criteria for common adverse events(CTCAE) grade\> 1 unrelieved toxicity of due to any prior treatment, excluding hair loss and peripheral sensory nerve disorders;
4. major surgical treatment or significant traumatic injury within 28 days prior to the start of study treatment (excluding needle aspiration, endoscopic biopsy for diagnostic purposes, etc.);
5. wounds or fractures that have not been cured for a long time;
6. Occurrence of arteriovenous/venous thrombosis events within 6 months, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.;
7. those who have a history of psychotropic drug abuse and cannot quit or have mental disorders;
8. Subject with any severe and/or uncontrolled disease, including:
1. Patients with poor blood pressure control after standard treatment (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥ 100mmHg);
2. Patients who have experienced myocardial ischemia or myocardial infarction within six months; New York Heart Association(NYHA )grade ≥2 congestive heart failure; Grade ≥2 atrioventricular block; Arrhythmias that cannot be stably controlled with drugs (including QTc ≥470ms) and arrhythmias that may have a potential impact on trial treatment;
3. Active infection ( CTCAE grade ≥ 2 infection);
4. Decompensated liver cirrhosis, active hepatitis \*;
\* active hepatitis (hepatitis B reference:Hepatitis B surface antigen( HBsAg )positive, and Hepatitis B virus DNA(HBV DNA)\>2500 copies /mL or \> 500 IU/mL; Hepatitis C reference: hepatitis C virus(HCV) antibody positive, and HCV virus titer test value exceeds the upper limit of normal value); Note: Subjects with positive surface antigen of hepatitis B or positive core antibody and hepatitis C patients eligible for inclusion are advised to continue antiviral therapy to prevent virus activation;
5. Active syphilis and active tuberculosis;
6. Renal failure requiring hemodialysis or peritoneal dialysis: glomerular filtration rate(eGFR) \< 15ml/ (min•1.73㎡);
7. A history of immunodeficiency, including Human Immunodeficiency Virus(HIV )positive or other acquired or congenital immunodeficiency disease, or a history of organ transplantation;
8. Poor control of diabetes (Fasting blood glucose (FBG) \> 10mmol/L, bedtime blood glucose \> 11.1mmol/L and hemoglobin A1C (HbA1c) ≥8.5% before bedtime);
9. Patients with urine protein ≥++ as indicated by routine urine examination, and 24-hour urine protein quantity \> 1.0g;
10. Persons suffering from epilepsy and requiring medical treatment.
* 2\) Tumor-related symptoms and treatment: a) Received surgery, chemotherapy, radiation or other anticancer therapy within 4 weeks before the start of study treatment (the washout period is calculated from the end of the last treatment); Those who had previously received local radiation therapy were eligible to enroll if they met the following criteria: the end of radiotherapy was more than 4 weeks before the start of study therapy (brain radiation was more than 2 weeks); The target lesions selected in this study are not in the radiotherapy region. Or the target lesion is located in the radiotherapy area, but progression is confirmed. b) Received the treatment of Chinese patent medicines with anti-tumor indications specified in the National Medical Products Administration(NMPA) approved drug instructions (including compound cantharidin capsules, Kangai injection, Kanglaite capsule/injection, Aidi injection, brucea javanica oil injection/capsule, Xiaoaiping tablet/injection, Huachansu capsule, etc.) within 2 weeks before the study treatment; c) Previously received immunomodulator therapy, including therapeutic vaccines, cytokine therapy, or Anti-programmed death receptor 1(anti-PD-1), Programmed death ligand-1(PD-L1), Cytotoxic T lymphocyte-associated protein 4(CTLA-4), High purity recombinant protein(4-1BB), T cell activation markers(OX-40) and other related immunotherapy drugs; d) pleural effusion, pericardial effusion, or ascites that uncontrolled and still requires repeated drainage (as determined by the investigator); e) Patients with brain metastasis whose symptom control stabilizes for less than 4 weeks after withdrawal of dehydrants and steroids (only for stage 2 patients with previous central nervous system metastases).
* 3\) Research treatment related: a) history of live attenuated vaccine administration within 28 days before the start of study treatment or planned live attenuated vaccine administration during the study period; b) Have a history of severe allergy to macromolecule drugs or known components of TQB2858 injection; c) An active autoimmune disease requiring systemic treatment (such as palliative drugs, corticosteroids, or immunosuppressants) occurred within 2 years before the start of study therapy. Alternative therapies (such as thyroxine, insulin, or physical corticosteroids for adrenal or pituitary dysfunction, etc.) are not considered systemic treatment; d) diagnosed as immunodeficient or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy (dose \>10mg/ d of prednisone or other equivalent hormone) and continued use within 2 weeks of initial administration; e) Participated in clinical trials of other antitumor drugs within 4 weeks before grouping.
* 4\) According to the researcher's judgment, subjects who have concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or who are considered unsuitable for inclusion for other reasons.
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Affiliated Tumor Hospital of Guangxi Medical University
Nanning, Guangxi, China
The Third Affiliated Hospital of Qiqihar Medical College
Qiqihar, Heilongjiang, China
Hunan Cancer Hospita
Changsha, Hunan, China
Affiliated Hospital of Changchun University of Chinese Medicine
Changchun, Jilin, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Linyi Tumor Hospital
Linyi, Shandong, China
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Qingdao Central Hospital
Qingdao, Shandong, China
The Second Affiliated Hospital of Shandong First Medical University
Taian, Shandong, China
Yantai Yuhuangding Hospital
Yantai, Shandong, China
Affiliated Peace Hospital of Changzhi Medical College
Changzhi, Shanxi, China
The First Affiliated Hospital of Xi 'an Jiaotong University
Xian, Shanxi, China
Sichuan Cancer Hospita
Chengdu, Sichuan, China
Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Li Li, Doctor
Role: primary
Xu Dong, Master
Role: primary
Jing Wang, Doctor
Role: primary
Jing Xuan, Doctor
Role: primary
Beihua Kong, Doctor
Role: primary
Youzhong Zhang, Doctor
Role: primary
Xiumin Li, Doctor
Role: primary
Xiaochun Zhang, Doctor
Role: primary
Li Sun, Doctor
Role: primary
Haiyan Liu, Master
Role: primary
Ying Yang, Doctor
Role: primary
Jianjun Wu, Bachelor
Role: primary
Zi Liu, Doctor
Role: primary
Yan Tan, Doctor
Role: primary
Qinlian Wen, Doctor
Role: primary
Qing Peng, Doctor
Role: primary
Ke Wang, Master
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TQB2858-Ⅰ-06
Identifier Type: -
Identifier Source: org_study_id